Urch Publishing | Publication

Therapeutic

Title

CNS Market Trends, 2007 to 2010

Sub title

Key Market Forecasts and Growth Opportunities

Author

S. Seget

Publication date

June 2007

ISBN

9781905751037

Pages

125

Price

pdf £995 | print £1050

Summary

The global market for drugs treating Central Nervous System (CNS) disorders has grown rapidly in recent years to reach US$55.5 billion in 2005, a year-on-year increase of 6.6%.

Between 2003 and 2005, global CNS sales increased by 19% and accounted for 9.2% of total global pharmaceutical sales in 2005. Annual global CNS sales growth slowed from 11.5% in 2004 to 6.6% in 2005 as a result of generic competition for leading anti-depressant and epilepsy therapies.

CNS Market Trends, 2007-2010 - Key market forecasts and growth opportunities provides an in-depth analysis of the growing market for pharmaceutical treatments for central nervous system (CNS) disorders.

This comprehensive report delivers market forecasts and overviews to help inform you in your pharmaceutical business decision-making.

Particular attention is drawn to the following drug classes; Epilepsy, Alzheimer's Disease, Migraines, ADHD, Parkinson's Disease.

Key findings from the report include:

The global CNS market is forecast to expand to US$63.9 billion in 2010 but growth will be limited by mature markets in depression and epilepsy and continued patent expiries for major products.

Of the top 20 products by global CNS sales in 2005, 13 generated annual sales in excess of US$1 billion.

5 of the top 10 CNS companies AstraZeneca, Forest, GSK, Sanofi-Aventis and Wyeth are forecast to grow their CNS sales over the next five years. J&J, Novartis and Abbott are forecast to suffer declining CNS sales over the next five years.

A total of 15 pharmaceutical companies were identified as having generated CNS sales in excess of US$1 billion in 2005.

Topamax was the leading epilepsy drug in 2005 with sales of US$1.7 billion. Other blockbuster epilepsy drugs include the second generation anti-convulsant, Lamictal and traditional anti-convulsant, Depakote.

The global market for CNS-related pharmaceuticals was dominated by the anti-depressant drug class with a market share of more than 30%

This report provides key information needed in your business including:

Sales forecast for top ten companies providing CNS treatment medicines.
Analysis of leading CNS products likely to loose patent protection in the next ten years.
Sales forecasts to 2010 for the top ten CNS medicines and forecasts by drug class.
Overview of disease incidence, areas of growth and breakdown of disease burden and mortality.
Breakdown of the major market trends and business opportunities.
In-depth coverage of the following companies' CNS market presence: Abbott, AstraZeneca, Eli Lilly, Forest, GlaxoSmithKline, Johnson & Johnson, Novartis, Pfizer, Sanofi-Aventis, Wyeth.

Use This Report To:
1. Benchmark your company's portfolio against market trends and forecasts to plan better for greater profitability.

2. Spot areas of pharmaceutical market growth and good opportunities for delivering successful sales growth.

3. Support your internal planning processes by using an external perspective founded on detailed analysis and transparent market forecasts.

The 135 page publication contains 53 Figures and 54 Tables to help you make sense of the wealth of data. This report will be of particular use to those involved in:
- pharmaceutical company corporate planning,
- portfolio management, and,
- market and sales forecasting.

The report is divided into five key sections. Chapters 2-5 present historical trends for key disease markets, key drug classes, key products and key companies. Chapter 6 outlines future CNS market trends and major growth opportunities. The data and analysis contained within the report are comprehensive, consistent and up-to-date and thus provide a single-point of reference for understanding CNS market trends.

TABLE OF CONTENTS

Executive Summary
Overview
Key disease markets
Key drug classes
Key products
Key companies
Key trends and opportunities

Chapter 1. Overview of Global CNS Market
Global CNS market
Report overview

Methodology
Sources

Chapter 2. Key CNS Disease Markets
Key CNS markets

Disease burden
CNS prevalence
CNS mortality

CNS epidemiology

ADHD (Attention Deficit Hyperactivity Disorder)
Alzheimer's disease
Depression
Epilepsy
Migraine
Parkinson's disease
Schizophrenia

Chapter 3. Key CNS Drug Classes
Key drug classifications
Anti-depressants drug class

Leading anti-depressant drugs

Anti-psychotics drug class

Leading anti-psychotics

Epilepsy drug class

Leading epilepsy drugs

Alzheimer's disease drug class

Leading Alzheimer's disease drugs

Migraine drug class

Leading migraine drugs

ADHD drug class

Leading ADHD drugs

Parkinson's disease drug class

Leading Parkinson's disease drugs

Selected other drug classes
Leading selected other CNS drugs

Chapter 4. Key CNS Products
Leading products
Top 10 leading CNS drugs

Zyprexa (olanzapine)
Risperdal (risperidone)
Effexor (venlafaxine)
Zoloft (sertraline)
Seroquel (quetiapine)
Lexapro/ Cipralex (escitalopram)
Aricept (donepezil)
Topamax (topiramate)
Lamictal (lamotrigine)
Wellbutrin (bupropion)

Chapter 5. Key Companies Involved in CNS
Major CNS players
Leading companies

Johnson & Johnson
Pfizer
Eli Lilly
GlaxoSmithKline
AstraZeneca
Wyeth
Novartis
Forest
Abbott
Sanofi-Aventis

Chapter 6. Key Trends and Opportunities in CNS
Key disease market forecasts

Global markets
CNS sites

Key drug class forecasts

Anti-depressants
Anti-psychotics
Epilepsy
Alzheimer's disease
Migraine
ADHD
Parkinson's disease

Selected others
Key product forecasts

Company forecasts in the CNS area

Johnson & Johnson
Pfizer
Eli Lilly
GlaxoSmithKline
AstraZeneca
Wyeth
Novartis
Forest
Abbott
Sanofi-Aventis

Appendix
Proprietary data sources
Product Trends Database
R&D Trends Database
Company Trends Database
Top 48 CNS products
Top 15 pharmaceutical companies by CNS sales

Figures
Figure 1: Global CNS market, 2003-2005
Figure 2: Report structure
Figure 3: Disease burden for CNS in seven major pharmaceutical markets, 2005
Figure 4: Prevalence for CNS in seven major pharmaceutical markets, 2005
Figure 5: CNS deaths in seven major pharmaceutical markets, 2005
Figure 6: CNS epidemiology in seven major markets, 2005
Figure 7: ADHD epidemiology in seven major markets, 2005
Figure 8: Alzheimer's disease epidemiology in seven major markets, 2005
Figure 9: Depression epidemiology in seven major markets, 2005
Figure 10: Epilepsy epidemiology in seven major markets, 2005
Figure 11: Migraine epidemiology in seven major markets, 2005
Figure 12: Parkinson's disease epidemiology in seven major markets, 2005
Figure 13: Schizophrenia epidemiology in seven major markets, 2005
Figure 14: Global CNS market by drug class, 2005
Figure 15: Global CNS market by drug class, 2003-2005
Figure 16: Global CNS market trends by drug class, 2004-2005
Figure 17: Anti-depressants drugs market, 2003-2005
Figure 18: Leading anti-depressant drugs by approval date, 1980-2005
Figure 19: Anti-psychotics drugs market, 2003-2005
Figure 20: Leading anti-psychotics by approval date, 1989-2005
Figure 21: Epilepsy drugs market, 2003-2005
Figure 22: Leading epilepsy drugs by approval date, 1968-2005
Figure 23: Alzheimer's disease drugs market, 2003-2005
Figure 24: Leading Alzheimer's disease drugs by approval date, 1996-2005
Figure 25: Migraine drugs market, 2003-2005
Figure 26: Leading migraine drugs by approval date, 1992-2005
Figure 27: ADHD drugs market, 2003-2005
Figure 28: Leading ADHD drugs by approval date, 1996-2005
Figure 29: Parkinson's disease market, 2003-2005
Figure 30: Leading Parkinson's disease drugs by approval date, 1997-2005
Figure 31: Selected others market, 2003-2005
Figure 32: Leading selected other CNS drugs by approval date, 1968-2005
Figure 33: Top 10 CNS products by global sales, 2005
Figure 34: Top 10 companies by global CNS sales, 2005
Figure 35: Top 10 companies by global CNS market share, 2005
Figure 36: Top 10 companies by global CNS sales, 2004-2005
Figure 37: CNS incidence forecasts by geographic market, 2005-2010
Figure 38: CNS incidence forecasts by disease market, 2005-2010
Figure 39: Global CNS market forecast, 2003-2010
Figure 40: Global CNS market forecasts by drug class, 2003-2010
Figure 41: Top 10 CNS drugs by forecast sales, 2010
Figure 42: Zyprexa (olanzapine) forecast sales, 2003-2010
Figure 43: Risperdal (risperidone) forecast sales, 2003-2010
Figure 44: Effexor (venlafaxine) forecast sales, 2003-2010
Figure 45: Zoloft (sertraline) forecast sales, 2003-2010
Figure 46: Seroquel (quetiapine) forecast sales, 2003-2010
Figure 47: Lexapro/ Cipralex (escitalopram) forecast sales, 2003-2010
Figure 48: Aricept (donepezil) forecast sales, 2003-2010
Figure 49: Topamax (topiramate) forecast sales, 2003-2010
Figure 50: Lamictal (lamotrigine) forecast sales, 2003-2010
Figure 51: Wellbutrin (bupropion) forecast sales, 2003-2010
Figure 52: Forecast patent expiries by 2005 global sales, 2006-2015
Figure 53: Top ten companies by CNS sales trends, 2005-2010

Tables
Table 1: Global CNS market trends by drug class, 2003-2005
Table 2: Leading anti-depressant drugs, 2005
Table 3: Anti-depressants market trends, 2003-2005
Table 4: Leading anti-psychotics, 2005
Table 5: Anti-psychotics market trends, 2003-2005
Table 6: Leading epilepsy drugs, 2005
Table 7: Epilepsy drug market trends, 2003-2005
Table 8: Leading Alzheimer's disease drugs, 2005
Table 9: Alzheimer's disease drug market trends, 2003-2005
Table 10: Leading migraine drugs, 2005
Table 11: Migraine drugs market trends, 2003-2005
Table 12: Leading ADHD drugs, 2005
Table 13: ADHD drugs market trends, 2003-2005
Table 14: Leading Parkinson's disease drugs, 2005
Table 15: Parkinson's disease market trends, 2003-2005
Table 16: Leading selected other CNS drugs, 2005
Table 17: selected others market trends, 2003-2005
Table 18: Top 20 CNS products by global sales, 2003-2005
Table 19: Zyprexa (olanzapine) profile, 2005
Table 20: Risperdal (risperidone) profile, 2005
Table 21: Effexor (venlafaxine) profile, 2005
Table 22: Zoloft (sertraline) profile, 2005
Table 23: Seroquel (quetiapine) profile, 2005
Table 24: Lexapro (escitalopram) profile, 2005
Table 25: Aricept (donepezil) profile, 2005
Table 26: Topamax (topiramate) profile, 2005
Table 27: Lamictal (lamotrigine) profile, 2005
Table 28: Wellbutrin (bupropion) profile, 2005
Table 29: Top 10 companies by global CNS sales, 2003-2005
Table 30: Johnson & Johnson profile, 2005
Table 31: Johnson & Johnson pipeline, 2005
Table 32: Pfizer profile, 2005
Table 33: Pfizer CNS pipeline, 2005
Table 34: Eli Lilly profile, 2005
Table 35: Eli Lilly CNS pipeline, 2005
Table 36: GlaxoSmithKline profile, 2005
Table 37: GlaxoSmithKline CNS pipeline, 2005
Table 38: AstraZeneca profile, 2005
Table 39: AstraZeneca CNS pipeline, 2005
Table 40: Wyeth profile, 2005
Table 41: Wyeth CNS pipeline, 2005
Table 42: Novartis profile, 2005
Table 43: Novartis CNS pipeline, 2005
Table 44: Forest profile, 2005
Table 45: Forest CNS pipeline, 2005
Table 46: Abbott profile, 2005
Table 47: Abbott CNS pipeline, 2005
Table 48: Sanofi-Aventis profile, 2005
Table 49: Sanofi-Aventis CNS pipeline, 2005
Table 50: Global CNS market forecasts by drug class, 2003-2010
Table 51: Top 10 CNS drugs forecasts, 2003-2010
Table 52: Top 10 companies by CNS sales forecasts, 2005-2010
Table 53: Top 48 CNS products by global pharmaceutical sales, 2003-2005
Table 54: Top 15 companies by global CNS sales, 2003-2005

Therapeutic

Steven Seget is Principal at Delphi Pharma, and provides independent strategic consulting services to the pharmaceutical and biotechnology industries.

Delphi Pharma provides strategic, financial and market–based solutions to clients, focusing primarily on the portfolio management and licensing functions.